Advertisements

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus.....»»

Category: press-releasesSource: businesswireindiaJun 14th, 2017

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 20th, 2017

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from Second Phase III Trial (RADIANCE™ Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTRIMS Meeting.....»»

Category: press-releasesSource: businesswireindiaOct 28th, 2017

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation.....»»

Category: press-releasesSource: businesswireindiaJun 7th, 2017

Uber launches #39;Movement#39; in India to support data-driven urban planning

Uber launches #39;Movement#39; in India to support data-driven urban planning.....»»

Category: topSource: moneycontrolApr 12th, 2018

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis

Glenmark Pharmaceuticals Announces Top-line Results From a Phase 3 Safety Study Evaluating Ryaltris in Patients With Perennial Allergic Rhinitis.....»»

Category: press-releasesSource: prnewswireDec 14th, 2017

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®.....»»

Category: press-releasesSource: businesswireindiaNov 7th, 2017

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD).....»»

Category: press-releasesSource: businesswireindiaNov 2nd, 2017

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer

Takeda to Feature ALUNBRIG™ (brigatinib) Data from Pivotal Phase 2 ALTA Trialat 18th World Conference on Lung Cancer.....»»

Category: press-releasesSource: businesswireindiaSep 28th, 2017

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients.....»»

Category: press-releasesSource: businesswireindiaAug 23rd, 2017

Glenmark’s dermatitis molecule displays positive results in phase-2a trial

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Category: featuresSource: livemintAug 1st, 2017

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting.....»»

Category: press-releasesSource: businesswireindiaJun 24th, 2017

Trai vs Bharti Airtel, Idea Cellular: TDSAT stays predatory pricing order - Business Standard

Trai vs Bharti Airtel, Idea Cellular: TDSAT stays predatory pricing order - Business Standard.....»»

Category: topSource: googlenews22 hr. 49 min. ago

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting.....»»

Category: press-releasesSource: businesswireindiaApr 24th, 2018

Iran oil imports fell 15.7 percent in fiscal year 2017/18

Iran oil imports fell 15.7 percent in fiscal year 2017/18.....»»

Category: global-financeSource: reutersApr 20th, 2018

BP and RIL sanction second phase of integrated KG-D6 development

BP and RIL sanction second phase of integrated KG-D6 development.....»»

Category: featuresSource: business-standardApr 19th, 2018

Airlines back creation of global drone registry: IATA

Airlines back creation of global drone registry: IATA.....»»

Category: topSource: moneycontrolApr 18th, 2018

Exclusive: South Korea"s KDB, GM Korea may sign preliminary funding deal by April 27

Exclusive: South Korea"s KDB, GM Korea may sign preliminary funding deal by April 27.....»»

Category: global-financeSource: reutersApr 17th, 2018

Exclusive: South Korea may sign GM Korea funding deal by April 27 - KDB chair

Exclusive: South Korea may sign GM Korea funding deal by April 27 - KDB chair.....»»

Category: global-financeSource: reutersApr 17th, 2018

Exclusive: South Korea"s KDB eyeing deal by April 27 to inject funds into GM Korea

Exclusive: South Korea"s KDB eyeing deal by April 27 to inject funds into GM Korea.....»»

Category: global-financeSource: reutersApr 17th, 2018